Drug Target Review2025-09-23T09:00:00
A new oral immunotherapy could change how peanut allergy is treated, targeting the gut to retrain the immune system and reduce the risk of life-threatening reactions. INP20’s nanoparticle technology promises a safer, more precise approach that could replace lifelong avoidance with lasting tolerance.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-07-31T06:00:00Z
Contributor Dr Davinder Ramsingh, Drug Target Review
2023-05-31T15:16:10
Sponsored by Bio-Techne
2023-04-04T15:03:09
Sponsored by Agilent
2023-07-04T10:05:58
Sponsored by Revvity
2026-07-08T07:58:00
Contributor Dr Nick Lynch, Dr Raminderpal Singh
2024-01-26T13:22:42
Sponsored by bit.bio
Site powered by Webvision Cloud